A Phase Ib/II Study to Evaluate Efficacy, Safety and Tolerability of KN046 Monotherapy or in Combination With Nab-paclitaxel in Subjects With Triple-negative Breast Cancer
Latest Information Update: 12 Jun 2023
At a glance
- Drugs Erfonrilimab (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Alphamab Biopharmaceuticals
Most Recent Events
- 07 Jun 2023 Status changed from active, no longer recruiting to completed.
- 10 Dec 2022 Results(As of May 9, 2022; n=27 ) assessing Efficacy, Safety, and Tolerability of KN046 in combination with Nab-paclitaxel in Metastatic Triple-negative Breast Cancer presented at the 45th Annual San Antonio Breast Cancer Symposium
- 16 Nov 2021 Planned End Date changed from 15 Sep 2021 to 15 Sep 2023.